Folate receptors including folate receptor α (FRα)
are overexpressed in up to 90% of ovarian cancers. Ovarian cancers
overexpressing FRα often exhibit high degrees of drug resistance
and poor outcomes. A porphyrin chassis has been developed that is
readily customizable according to the desired targeting properties.
Thus, compound O5 includes a free base porphyrin, two water-solubilizing
groups that project above and below the macrocycle plane, and a folate
targeting moiety. Compound O5 was synthesized (>95% purity) and
exhibited
aqueous solubility of at least 0.48 mM (1 mg/mL). Radiolabeling of
O5 with 64Cu in HEPES buffer at 37 °C gave a molar
activity of 1000 μCi/μg (88 MBq/nmol). [64Cu]Cu–O5
was stable in human serum for 24 h. Cell uptake studies showed 535
± 12% bound/mg [64Cu]Cu–O5 in FRα-positive
IGROV1 cells when incubated at 0.04 nM. Subcellular fractionation
showed that most radioactivity was associated with the cytoplasmic
(39.4 ± 2.7%) and chromatin-bound nuclear (53.0 ± 4.2%)
fractions. In mice bearing IGROV1 xenografts, PET imaging studies
showed clear tumor uptake of [64Cu]Cu–O5 from 1
to 24 h post injection with a low degree of liver uptake. The tumor
standardized uptake value at 24 h post injection was 0.34 ± 0.16
versus 0.06 ± 0.07 in the blocking group. In summary, [64Cu]Cu–O5 was synthesized at high molar activity, was stable
in serum, exhibited high binding to FRα-overexpressing cells
with high nuclear translocation, and gave uptake that was clearly
visible in mouse tumor xenografts.